Milestone Scientific Inc. (NASDAQ:MLSS)‘s stock had its “buy” rating reaffirmed by equities researchers at Maxim Group in a report released on Friday. They presently have a $4.00 price objective on the stock. Maxim Group’s target price indicates a potential upside of 220.00% from the company’s previous close.

Milestone Scientific (MLSS) traded up 8.00% during midday trading on Friday, reaching $1.35. 15,970 shares of the company’s stock were exchanged. Milestone Scientific has a 1-year low of $1.08 and a 1-year high of $2.15. The firm’s 50-day moving average is $1.26 and its 200 day moving average is $1.35. The stock’s market cap is $44.54 million.

COPYRIGHT VIOLATION NOTICE: “Milestone Scientific’s (MLSS) “Buy” Rating Reiterated at Maxim Group” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/06/milestone-scientifics-mlss-buy-rating-reiterated-at-maxim-group.html.

About Milestone Scientific

Milestone Scientific Inc (Milestone) is engaged in providing computer-controlled injection technologies and solutions for the medical and dental markets. The Company uses its CompuFlo technology for the delivery of medicaments. The CompuFlo pressure or force Computer-Controlled Local Anesthetic Delivery (C-CLAD) technology is a medical technology for the delivery of drugs, anesthetics and other medicaments into various tissue types.

Receive News & Ratings for Milestone Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.